In the study by Million et al. pretreatment with NGD 98–2 or NGD 9002 (both CRH-R1 antagonists) reduced the ICV CRH induced FPO, but when CRH was administered by IP injection, only NGD 9002 reduced FPO [33]. Here, CRHR1 is linked to otopalatodigital syndrome type 2.